ResearcherUniversity of BernActive in the last 2 years
Steve Robatel
Matched on OpenAlex author ID A5025318817. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 3
- Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02347-y↗
- TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.omton.2025.201034↗
- Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. Co-author DOI 10.3390/cancers14040985↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mirjam Schenk · 3 shared papers, 2022–2026 · strength 0.82
- Paper Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. DOI 10.3390/cancers14040985↗
- Paper Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal aden… DOI 10.1007/s00535-026-02347-y↗
- Paper TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma. DOI 10.1016/j.omton.2025.201034↗
- Martin Wartenberg · 2 shared papers, 2025–2026 · strength 0.49
- Max Nobis · 1 shared paper, 2026 · strength 0.25
- Ulf Kessler · 1 shared paper, 2026 · strength 0.25
- Lina Gross · 1 shared paper, 2025 · strength 0.24
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.